{"authors": [["Avila-Vazquez", "Maria Fernanda", "MF", "Unidad de Investigaci\u00f3n en Enfermedades Metab\u00f3licas, Centro M\u00e9dico Nacional Siglo XXI, IMSS, Mexico City 06720, Mexico. feravilaibero@gmail.com."], ["Altamirano-Bustamante", "Nelly F", "NF", "Instituto Nacional de Pediatr\u00eda, Mexico City 04530, Mexico. nellyab34@gmail.com."], ["Altamirano-Bustamante", "Myriam M", "MM", "Unidad de Investigaci\u00f3n en Enfermedades Metab\u00f3licas, Centro M\u00e9dico Nacional Siglo XXI, IMSS, Mexico City 06720, Mexico. myriamab@unam.mx."]], "text": "Conformational diseases represent a new aspect of proteomic medicine where diagnostic and therapeutic paradigms are evolving. In this context, the early biomarkers for target cell failure (neurons, \u03b2-cells, etc.) represent a challenge to translational medicine and play a multidimensional role as biomarkers and potential therapeutic targets. This systematic review, which follows the PICO and Prisma methods, analyses this new-fangled multidimensionality, its strengths and limitations, and presents the future possibilities it opens up. The nuclear diagnosis methods are immunoassays: ELISA, immunodot, western blot, etc., while the therapeutic approach is focused on pharmaco- and molecular chaperones.", "id": "29286329", "date": "2017-12-29", "title": "Amyloid Biomarkers in Conformational Diseases at Face Value: A Systematic Review.", "doi": "10.3390/molecules23010079", "journal": ["Molecules (Basel, Switzerland)", "Molecules"]}